-Second of Two Planned Trials Combining
ADCETRIS and Opdivo Under Clinical Collaboration Agreement-
Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb
(NYSE:BMY) today announced that the companies have initiated a
phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in
combination with Opdivo (nivolumab) for patients with
CD30-expressing relapsed or refractory B-cell and T-cell
non-Hodgkin lymphomas (NHL), including diffuse large B-cell
lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL) and cutaneous
T-cell lymphoma (CTCL). This is the second of two trials being
conducted under a previously announced clinical trial collaboration
agreement between Bristol-Myers Squibb Company and Seattle
Genetics. ADCETRIS is an antibody-drug conjugate (ADC) directed to
CD30, a marker expressed on Hodgkin lymphoma (HL) and several types
of NHL, which combines the targeting ability of a monoclonal
antibody with a highly potent cell-killing agent. Recent
preclinical data suggest that ADCETRIS causes immunogenic cell
death of tumor cells, providing rationale for combination with
Opdivo, a human antibody that targets and inhibits the programmed
death receptor-1 (PD-1), resulting in T-cell activation. Opdivo is
part of a new class of cancer immunotherapy treatments known as
checkpoint inhibitors, which are designed to harness the body’s own
immune system in fighting cancer by targeting distinct regulatory
components of the immune system.
“This is the second corporate-sponsored clinical trial to
evaluate ADCETRIS combined with a checkpoint inhibitor to determine
if the combination can improve patient outcomes,” said Jonathan
Drachman, M.D., Chief Medical Officer and Executive Vice President,
Research and Development at Seattle Genetics. “This study is a part
of a broad development program that includes more than 70 ongoing
clinical trials evaluating ADCETRIS in multiple lines of therapy
for Hodgkin and non-Hodgkin lymphoma and as part of novel
combinations that could result in improved clinical benefit with
manageable safety profiles. Our goal is to establish ADCETRIS as
the foundation of care for CD30-expressing lymphomas.”
The phase 1/2 open-label, multi-center, clinical trial is
designed to evaluate the safety, tolerability and antitumor
activity of ADCETRIS in combination with Opdivo in patients with
relapsed or refractory CD30-expressing NHL. The study will consist
of a phase 1 dose evaluation portion followed by a single-arm phase
2 portion that will expand enrollment to treat disease-specific
cohorts with relapsed or refractory DLBCL, PTCL or CTCL at the
recommended dose level and treatment schedule. The primary
endpoints are safety, tolerability and objective response rate of
the combination of ADCETRIS with Opdivo. The secondary endpoints
include duration of response, complete response rate with the
combination regimen, duration of complete response,
progression-free survival and overall survival. The trial is being
conducted at multiple centers in the United States, Canada and
Europe and is designed to enroll approximately 120 patients.
“Bristol-Myers Squibb continues to strengthen its
industry-leading development program for Opdivo and its rapidly
expanding hematology portfolio,” said Michael Giordano, senior vice
president, Head of Development, Oncology, Bristol-Myers Squibb. “We
are pleased to collaborate with Seattle Genetics on clinical
research that focuses on novel combination regimens in areas of
serious unmet need.”
In addition to the two ongoing Opdivo combination trials under
the collaboration with Bristol-Myers Squibb, ADCETRIS is being
evaluated in more than 70 ongoing clinical trials including the
ECHELON-1 phase 3 trial in frontline HL, the ECHELON-2 phase 3
trial in frontline mature T-cell lymphoma and the ALCANZA phase 3
trial in CTCL. Opdivo is being evaluated either as monotherapy or
in combination with other therapies in some of the hardest-to-treat
hematologic cancers, including multiple myeloma, chronic
myelogenous leukemia, and Hodgkin and non-Hodgkin lymphomas
including follicular and DLBCL. Opdivo has Breakthrough Therapy
designation for the treatment of patients with Hodgkin lymphoma
after failure of autologous stem cell transplant and brentuximab
vedotin.
ADCETRIS is not currently approved for frontline treatment or
for the treatment of NHL other than relapsed systemic anaplastic
large cell lymphoma (sALCL). Opdivo is not currently approved for
the treatment of lymphoma.
About ADCETRIS® (Brentuximab Vedotin)
ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody
attached by a protease-cleavable linker to a microtubule disrupting
agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’
proprietary technology. The ADC employs a linker system that is
designed to be stable in the bloodstream but to release MMAE upon
internalization into CD30-expressing tumor cells. CD30 is a member
of the tumor necrosis factor receptor (TNFR) superfamily. In HL,
CD30 may be involved in tumor cell proliferation by interacting
with immune cells in the tumor microenvironment.
ADCETRIS for intravenous injection has received approval from
the FDA for three indications: (1) regular approval for the
treatment of patients with classical HL after failure of autologous
hematopoietic stem cell transplantation (auto-HSCT) or after
failure of at least two prior multi-agent chemotherapy regimens in
patients who are not auto-HSCT candidates, (2) regular approval for
the treatment of classical HL patients at high risk of relapse or
progression as post-auto-HSCT consolidation, and (3) accelerated
approval for the treatment of patients with systemic anaplastic
large cell lymphoma (sALCL) after failure of at least one prior
multi-agent chemotherapy regimen. The sALCL indication is approved
under accelerated approval based on overall response rate.
Continued approval for the sALCL indication may be contingent upon
verification and description of clinical benefit in confirmatory
trials. Health Canada granted ADCETRIS approval with conditions for
relapsed or refractory HL and sALCL.
ADCETRIS was granted conditional marketing authorization by the
European Commission in October 2012 for two indications: (1) for
the treatment of adult patients with relapsed or refractory
CD30-positive HL following autologous stem cell transplant (ASCT),
or following at least two prior therapies when ASCT or multi-agent
chemotherapy is not a treatment option, and (2) the treatment of
adult patients with relapsed or refractory sALCL. ADCETRIS has
received marketing authorization by regulatory authorities in more
than 55 countries. See important safety information below.
Seattle Genetics and Takeda Pharmaceutical Company Limited
(Takeda) are jointly developing ADCETRIS. Under the terms of the
collaboration agreement, Seattle Genetics has U.S. and Canadian
commercialization rights and Takeda has rights to commercialize
ADCETRIS in the rest of the world. Seattle Genetics and Takeda are
funding joint development costs for ADCETRIS on a 50:50 basis,
except in Japan where Takeda is solely responsible for development
costs.
About Opdivo
Bristol-Myers Squibb has a broad, global development program to
study Opdivo in multiple tumor types consisting of more than 50
trials – as monotherapy or in combination with other therapies – in
which more than 8,000 patients have been enrolled worldwide. Opdivo
is the first PD-1 immune checkpoint inhibitor to receive regulatory
approval anywhere in the world in July 2014, and currently has
regulatory approval in more than 40 countries including the United
States, Japan, and in the European Union.
About Lymphoma
Lymphoma is a general term for a group of cancers that originate
in the lymphatic system. There are two major categories of
lymphoma: HL and NHL. HL is distinguished from other types of
lymphoma by the presence of one characteristic type of cell, known
as the Reed-Sternberg cell. The Reed-Sternberg cell generally
expresses CD30. NHL is further categorized into indolent
(low-grade) or aggressive, including DLBCL. DLBCL is the most
common type of NHL.
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the
development and commercialization of innovative antibody-based
therapies for the treatment of cancer. Seattle Genetics is leading
the field in developing antibody-drug conjugates (ADCs), a
technology designed to harness the targeting ability of antibodies
to deliver cell-killing agents directly to cancer cells. The
company’s lead product, ADCETRIS® (brentuximab vedotin) is a
CD30-targeted ADC that, in collaboration with Takeda Pharmaceutical
Company Limited, is commercially available in more than 55
countries, including the U.S., Canada, Japan and members of the
European Union. Additionally, ADCETRIS is being evaluated broadly
in more than 70 ongoing clinical trials in CD30-expressing
malignancies. Seattle Genetics is also advancing a robust pipeline
of clinical-stage programs, including vadastuximab talirine
(SGN-CD33A; 33A), denintuzumab mafodotin (SGN-CD19A; 19A),
SGN-LIV1A, SGN-CD70A, ASG-22ME, ASG-15ME and SEA-CD40. Seattle
Genetics has collaborations for its ADC technology with a number of
leading biotechnology and pharmaceutical companies, including
AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech,
GlaxoSmithKline and Pfizer. More information can be found at
www.seattlegenetics.com.
Immuno-Oncology at Bristol-Myers Squibb
Surgery, radiation, cytotoxic or targeted therapies have
represented the mainstay of cancer treatment over the last several
decades, but long-term survival and a positive quality of life have
remained elusive for many patients with advanced disease.
To address this unmet medical need, Bristol-Myers Squibb is
leading research in an innovative field of cancer research and
treatment known as Immuno-Oncology, which involves agents whose
primary mechanism is to work directly with the body’s immune system
to fight cancer. The company is exploring a variety of compounds
and immunotherapeutic approaches for patients with different types
of cancer, including researching the potential of combining
Immuno-Oncology agents that target different pathways in the
treatment of cancer.
Bristol-Myers Squibb is committed to advancing the science of
Immuno-Oncology, with the goal of changing survival expectations
and the way patients live with cancer.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit www.bms.com or follow
us on Twitter at http://twitter.com/bmsnews.
ADCETRIS (brentuximab vedotin) U.S. Important Safety
Information
BOXED WARNING
Progressive multifocal leukoencephalopathy (PML): JC virus
infection resulting in PML and death can occur in patients
receiving ADCETRIS® (brentuximab vedotin).
Contraindication
ADCETRIS is contraindicated with concomitant bleomycin due to
pulmonary toxicity (e.g., interstitial infiltration and/or
inflammation).
Warnings and Precautions
- Peripheral neuropathy: ADCETRIS
treatment causes a peripheral neuropathy that is predominantly
sensory. Cases of peripheral motor neuropathy have also been
reported. ADCETRIS-induced peripheral neuropathy is cumulative.
Monitor patients for symptoms of neuropathy, such as hypoesthesia,
hyperesthesia, paresthesia, discomfort, a burning sensation,
neuropathic pain or weakness and institute dose modifications
accordingly.
- Anaphylaxis and infusion
reactions: Infusion-related reactions, including anaphylaxis,
have occurred with ADCETRIS. Monitor patients during infusion. If
an infusion-related reaction occurs, interrupt the infusion and
institute appropriate medical management. If anaphylaxis occurs,
immediately and permanently discontinue the infusion and administer
appropriate medical therapy.
- Hematologic toxicities:
Prolonged (≥1 week) severe neutropenia and Grade 3 or 4
thrombocytopenia or anemia can occur with ADCETRIS. Febrile
neutropenia has been reported with ADCETRIS. Monitor complete blood
counts prior to each dose of ADCETRIS and consider more frequent
monitoring for patients with Grade 3 or 4 neutropenia. Monitor
patients for fever. If Grade 3 or 4 neutropenia develops, consider
dose delays, reductions, discontinuation, or G-CSF prophylaxis with
subsequent doses.
- Serious infections and opportunistic
infections: Infections such as pneumonia, bacteremia, and
sepsis or septic shock (including fatal outcomes) have been
reported in patients treated with ADCETRIS. Closely monitor
patients during treatment for the emergence of possible bacterial,
fungal or viral infections.
- Tumor lysis syndrome: Closely
monitor patients with rapidly proliferating tumor and high tumor
burden.
- Increased toxicity in the presence
of severe renal impairment: The frequency of ≥Grade 3 adverse
reactions and deaths was greater in patients with severe renal
impairment compared to patients with normal renal function. Avoid
the use of ADCETRIS in patients with severe renal impairment.
- Increased toxicity in the presence
of moderate or severe hepatic impairment: The frequency of
≥Grade 3 adverse reactions and deaths was greater in patients with
moderate or severe hepatic impairment compared to patients with
normal hepatic function. Avoid the use of ADCETRIS in patients with
moderate or severe hepatic impairment.
- Hepatotoxicity: Serious cases of
hepatotoxicity, including fatal outcomes, have occurred with
ADCETRIS. Cases were consistent with hepatocellular injury,
including elevations of transaminases and/or bilirubin, and
occurred after the first dose of ADCETRIS or rechallenge.
Preexisting liver disease, elevated baseline liver enzymes, and
concomitant medications may also increase the risk. Monitor liver
enzymes and bilirubin. Patients experiencing new, worsening, or
recurrent hepatotoxicity may require a delay, change in dose, or
discontinuation of ADCETRIS.
- Progressive multifocal
leukoencephalopathy (PML): JC virus infection resulting in PML
and death has been reported in ADCETRIS-treated patients. First
onset of symptoms occurred at various times from initiation of
ADCETRIS therapy, with some cases occurring within 3 months of
initial exposure. In addition to ADCETRIS therapy, other possible
contributory factors include prior therapies and underlying disease
that may cause immunosuppression. Consider the diagnosis of PML in
any patient presenting with new-onset signs and symptoms of central
nervous system abnormalities. Hold ADCETRIS if PML is suspected and
discontinue ADCETRIS if PML is confirmed.
- Pulmonary Toxicity: Events of
noninfectious pulmonary toxicity including pneumonitis,
interstitial lung disease, and acute respiratory distress syndrome,
some with fatal outcomes, have been reported. Monitor patients for
signs and symptoms of pulmonary toxicity, including cough and
dyspnea. In the event of new or worsening pulmonary symptoms, hold
ADCETRIS dosing during evaluation and until symptomatic
improvement.
- Serious dermatologic reactions:
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis
(TEN), including fatal outcomes, have been reported with ADCETRIS.
If SJS or TEN occurs, discontinue ADCETRIS and administer
appropriate medical therapy.
- Embryo-fetal toxicity: Fetal
harm can occur. Advise pregnant women of the potential hazard to
the fetus.
Most Common Adverse Reactions:
ADCETRIS was studied as monotherapy in 160 patients with
relapsed classical HL and sALCL in two uncontrolled single-arm
trials. Across both trials, the most common adverse reactions
(≥20%), regardless of causality, were neutropenia, peripheral
sensory neuropathy, fatigue, nausea, anemia, upper respiratory
tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough
and vomiting.
ADCETRIS was studied in 329 patients with classical HL at high
risk of relapse or progression post-auto-HSCT in a
placebo-controlled randomized trial. The most common adverse
reactions (≥20%) in the ADCETRIS-treatment arm (167 patients),
regardless of causality, were neutropenia, peripheral sensory
neuropathy, thrombocytopenia, anemia, upper respiratory tract
infection, fatigue, peripheral motor neuropathy, nausea, cough, and
diarrhea.
Drug Interactions:
Concomitant use of strong CYP3A4 inhibitors or inducers, or P-gp
inhibitors, has the potential to affect the exposure to monomethyl
auristatin E (MMAE).
Use in Specific Populations:
MMAE exposure and adverse reactions are increased in patients
with moderate or severe hepatic impairment or severe renal
impairment. Avoid use.
For additional Important Safety Information, including Boxed
WARNING, please see the full Prescribing Information for ADCETRIS
at http://www.seattlegenetics.com/pdf/adcetris_USPI.pdf.
Indication and Important Safety Information for
OPDIVO® (nivolumab)
INDICATION
OPDIVO® (nivolumab) is indicated for the treatment of patients
with metastatic non-small cell lung cancer (NSCLC) with progression
on or after platinum-based chemotherapy. Patients with EGFR or ALK
genomic tumor aberrations should have disease progression on
FDA-approved therapy for these aberrations prior to receiving
OPDIVO.
IMPORTANT SAFETY INFORMATION
Immune-Mediated Pneumonitis
Immune-mediated pneumonitis or interstitial lung disease,
including fatal cases, occurred with OPDIVO treatment. Across the
clinical trial experience with solid tumors, fatal immune-mediated
pneumonitis occurred with OPDIVO. Monitor patients for signs with
radiographic imaging and symptoms of pneumonitis. Administer
corticosteroids for Grade 2 or greater pneumonitis. Permanently
discontinue OPDIVO for Grade 3 or 4 and withhold until resolution
for Grade 2. In Checkmate 057, immune-mediated pneumonitis,
including interstitial lung disease, occurred in 3.4% (10/287) of
patients receiving OPDIVO: Grade 3 (n=5), Grade 2 (n=2), and Grade
1 (n=3).
Immune-Mediated Colitis
Immune-mediated colitis can occur with OPDIVO treatment. Monitor
patients for signs and symptoms of colitis. Administer
corticosteroids for Grade 2 (of more than 5 days duration), 3, or 4
colitis. Withhold OPDIVO for Grade 2 or 3 and permanently
discontinue for Grade 4 or recurrent colitis upon restarting
OPDIVO. In Checkmate 057, diarrhea or colitis occurred in 17%
(50/287) of patients receiving OPDIVO. Immune-mediated colitis
occurred in 2.4% (7/287) of patients: Grade 3 (n=3), Grade 2 (n=2),
and Grade 1 (n=2).
Immune-Mediated Hepatitis
Immune-mediated hepatitis can occur with OPDIVO treatment.
Monitor patients for abnormal liver tests prior to and periodically
during treatment. Administer corticosteroids for Grade 2 or greater
transaminase elevations. Withhold OPDIVO for Grade 2 and
permanently discontinue for Grade 3 or 4 immune-mediated hepatitis.
In Checkmate 057, one patient (0.3%) developed immune-mediated
hepatitis.
Immune-Mediated Endocrinopathies
Hypophysitis, adrenal insufficiency, thyroid disorders, and type
1 diabetes mellitus can occur with OPDIVO treatment. Monitor
patients for signs and symptoms of hypophysitis, signs and symptoms
of adrenal insufficiency during and after treatment, thyroid
function prior to and periodically during treatment and
hyperglycemia. Administer corticosteroids for Grade 2 or greater
hypophysitis. Withhold OPDIVO for Grade 2 or 3 and permanently
discontinue for Grade 4 hypophysitis. Administer corticosteroids
for Grade 3 or 4 adrenal insufficiency. Withhold OPDIVO for Grade 2
and permanently discontinue for Grade 3 or 4 adrenal insufficiency.
Administer hormone replacement therapy for hypothyroidism. Initiate
medical management for control of hyperthyroidism. Administer
insulin for type 1 diabetes. Withhold OPDIVO for Grade 3 and
permanently discontinue for Grade 4 hyperglycemia. In Checkmate
037, 066, and 057, <1.0% of OPDIVO-treated patients developed
adrenal insufficiency. In Checkmate 057, Grade 1 or 2
hypothyroidism, including thyroiditis, occurred in 7% (20/287) and
elevated TSH occurred in 17% of patients receiving OPDIVO. Grade 1
or 2 hyperthyroidism occurred in 1.4% (4/287) of patients.
Immune-Mediated Nephritis and Renal Dysfunction
Immune-mediated nephritis can occur with OPDIVO treatment.
Monitor patients for elevated serum creatinine prior to and
periodically during treatment. For Grade 2 or 3 increased serum
creatinine, withhold OPDIVO and administer corticosteroids; if
worsening or no improvement occurs, permanently discontinue OPDIVO.
Administer corticosteroids for Grade 4 serum creatinine elevation
and permanently discontinue OPDIVO. In Checkmate 057, Grade 2
immune-mediated renal dysfunction occurred in 0.3% (1/287) of
patients receiving OPDIVO.
Immune-Mediated Rash
Immune-mediated rash can occur with OPDIVO treatment. Severe
rash (including rare cases of fatal toxic epidermal necrolysis)
occurred in the clinical program of OPDIVO. Monitor patients for
rash. Administer corticosteroids for Grade 3 or 4 rash. Withhold
OPDIVO for Grade 3 and permanently discontinue for Grade 4. In
Checkmate 057, immune-mediated rash occurred in 6% (17/287) of
patients receiving OPDIVO, including four Grade 3 cases.
Immune-Mediated Encephalitis
Immune-mediated encephalitis can occur with OPDIVO treatment.
Withhold OPDIVO in patients with new-onset moderate to severe
neurologic signs or symptoms and evaluate to rule out other causes.
If other etiologies are ruled out, administer corticosteroids and
permanently discontinue OPDIVO for immune-mediated encephalitis.
Across clinical trials of 8490 patients receiving OPDIVO as a
single agent or in combination with ipilimumab, <1.0% of
patients were identified as having encephalitis. In Checkmate 057,
fatal limbic encephalitis occurred in one patient (0.3%) receiving
OPDIVO.
Other Immune-Mediated Adverse Reactions
Based on the severity of the adverse reaction, permanently
discontinue or withhold treatment, administer high-dose
corticosteroids, and, if appropriate, initiate hormone-replacement
therapy. The following clinically significant immune-mediated
adverse reactions occurred in <1.0% of OPDIVO-treated patients:
uveitis, pancreatitis, facial and abducens nerve paresis,
demyelination, polymyalgia rheumatica, autoimmune neuropathy,
Guillain-Barre syndrome, hypopituitarism, and systemic inflammatory
response syndrome. Across clinical trials of OPDIVO as a single
agent administered at doses 3 mg/kg and 10 mg/kg, additional
clinically significant, immune-mediated adverse reactions were
identified: motor dysfunction, vasculitis, and myasthenic
syndrome.
Infusion Reactions
Severe infusion reactions have been reported in <1.0% of
patients in clinical trials of OPDIVO as a single agent.
Discontinue OPDIVO in patients with Grade 3 or 4 infusion
reactions. Interrupt or slow the rate of infusion in patients with
Grade 1 or 2. In Checkmate 057 and 066, Grade 2 infusion reactions
occurred in 1.0% (5/493) of patients receiving OPDIVO.
Embryofetal Toxicity
Based on its mechanism of action, OPDIVO can cause fetal harm
when administered to a pregnant woman. Advise pregnant women of the
potential risk to a fetus. Advise females of reproductive potential
to use effective contraception during treatment with an
OPDIVO-containing regimen and for at least 5 months after the last
dose of OPDIVO.
Lactation
It is not known whether OPDIVO is present in human milk. Because
many drugs, including antibodies, are excreted in human milk and
because of the potential for serious adverse reactions in nursing
infants from OPDIVO-containing regimen, advise women to discontinue
breastfeeding during treatment.
Serious Adverse Reactions
In Checkmate 057, serious adverse reactions occurred in 47% of
patients receiving OPDIVO. The most frequent serious adverse
reactions reported in ≥2% of patients were pneumonia, pulmonary
embolism, dyspnea, pleural effusion, and respiratory failure.
Common Adverse Reactions
In Checkmate 057, the most common adverse reactions (≥20%)
reported with OPDIVO were fatigue (49%), musculoskeletal pain
(36%), cough (30%), decreased appetite (29%), and constipation
(23%).
Please see U.S. Full Prescribing Information for OPDIVO.
Seattle Genetics Forward-Looking Statement
Certain of the statements made in this press release are
forward-looking, such as those, among others, relating to the
future potential therapeutic uses of ADCETRIS (including in
combination with Opdivo) and future clinical and regulatory
progress. Actual results or developments may differ materially from
those projected or implied in these forward-looking statements.
Factors that may cause such a difference include risks related to
adverse clinical results associated with the use of ADCETRIS or
Opdivo (or the combination), the failure of the companies to
continue their collaboration or execute on the planned clinical
trials or adverse regulatory action More information about the
risks and uncertainties faced by Seattle Genetics is contained
under the caption “Risk Factors” included in the company’s
Quarterly Report on Form 10-Q for the quarter ended September 30,
2015 filed with the Securities and Exchange
Commission. Seattle Genetics disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Bristol-Myers Squibb Forward-Looking Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Among other risks, there can be no guarantee
that Opdivo will receive approval for any additional indications
described herein or, if approved, become commercially successful in
such indications. Forward-looking statements in this press release
should be evaluated together with the many uncertainties that
affect Bristol-Myers Squibb's business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb's Annual Report on Form 10-K for the year ended December 31,
2014 in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151223005045/en/
Investors:Seattle Genetics, Inc.Peggy Pinkston,
425-527-4160ppinkston@seagen.comorBristol-Myers SquibbRanya Dajani,
609-252-5330ranya.dajani@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.comorMedia:Seattle Genetics,
Inc.Tricia Larson, 425-527-4180tlarson@seagen.comorBristol-Myers
SquibbAudrey Abernathy, 919-605-4521audrey.abernathy@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024